PRLog (Press Release) –
Covance (Madison, Wisconsin) has begun offering pharmacokinetic studies using B-Clear, described as the only in-vitro method to predict in-vivo liver disposition. The company licensed B-Clear from Qualyst (Raleigh, North Carolina), a specialist in ADMET (absorption, distribution, metabolism, excretion and toxicology) technology, in October 2006. Terms of the deal were not disclosed.
B-Clear is a sandwich-cultured hepatocyte system that predicts hepatobiliary disposition, including hepatic uptake, hepatic accumulation, biliary clearance and drug transport. It can be used as a screen for lead optimisation during drug discovery and to address drug transport questions during development. It is said to enable better prediction of bioavailability, pharmacokinetics, species-specific drug dosing and candidate selection.
Covance will initially offer B-Clear-HU (primary human) and B-Clear-RT (primary rat) hepatocytes for hepatobiliary disposition and hepatic transport studies. Services using non-human primate, canine and mouse hepatocytes are expected to become available in late 2007. Submitted by www.jobs4dd.com E-mail : info@jobs4dd.com
